Results for tag: "Breast Cancer Immunotherapy"

Breast cancer immunotherapy is a branch of oncological treatment within the broader context of women's health, which focuses on harnessing the patient's immune system to fight cancer cells. While surgery, chemotherapy, radiation, and hormone therapy have long been the cornerstones of breast cancer treatment, the emergence of immunotherapy has offered new hope in managing this prevalent disease affecting women worldwide. Immunotherapy includes treatments such as checkpoint inhibitors, monoclonal antibodies, cancer vaccines, and other modalities that aim to boost or direct the patient’s immune response against cancer cells. Breast cancer immunotherapy has become especially pertinent in treating certain aggressive types such as triple-negative breast cancer, wherein patients have limited treatment options due to the absence of hormone receptors and HER2 protein. The integration of immunotherapy into the treatment paradigm for breast cancer represents a promising advance in women's health, as it may improve survival rates and the quality of life for patients with breast cancer. Key players in the breast cancer immunotherapy market consist of established pharmaceutical and biotechnology companies as well as emerging enterprises that are at the forefront of research and development. Prominent companies in the market include Roche, Merck & Co., AstraZeneca, Pfizer, and Bristol Myers Squibb. These companies are actively involved in the development and commercialization of immunotherapeutic drugs and therapies that have the potential to redefine breast cancer treatment regimens. Show Less Read more